BL0020 and Toripalimab for Recurring Small Cell Lung Cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a combination of two drugs (BL0020 and Toripalimab) in patients whose small cell lung cancer has come back after initial chemotherapy treatment. The goal is to see if this combination is safe and can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with extensive-stage small cell lung cancer that has come back or gotten worse after your first round of chemotherapy
- Your cancer came back more than 30 days after your last chemotherapy dose
- You are generally healthy enough for treatment (able to be up and about most of the day)
- You do not have active brain tumors or certain autoimmune diseases like lupus, rheumatoid arthritis, or Crohn's disease
- You are not pregnant or breastfeeding, and do not have HIV, active hepatitis B or C, or uncontrolled high blood pressure
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, BL0020, for people whose non-small cell lung cancer with an EGFR mutation has turned into small cell lung cancer after EGFR-targeted therapy. It aims to see if BL0020 is safe and effective for this specific change.
This trial tests whether adding toripalimab (an immunotherapy) or toripalimab plus another immunotherapy (tifcemalimab) after standard chemoradiation can help prevent small cell lung cancer from coming back. It is for people with limited-stage disease who have finished initial treatment without the cancer growing.
This Phase 2 trial tests how well two study drugs (and a combination of them) work in people with extensive-stage small cell lung cancer. It’s mainly for patients whose cancer has come back or who couldn’t tolerate at least some standard treatments, and it aims to see if treatment can shrink tumors and be tolerable.
This trial tests whether a combination of two immunotherapy drugs (toripalimab and JS004) plus chemotherapy can help control relapsed or extensive-stage small cell lung cancer. It is designed for people whose cancer has spread or returned and who are generally healthy enough to receive strong treatment.
This trial tests whether a combination of toripalimab (an immunotherapy drug) and chemotherapy can help prevent small cell lung cancer from coming back after surgery. It is for people who had an unexpected finding of small cell lung cancer after their tumor was removed.
This trial tests a combination of the immunotherapy drug toripalimab with standard chemotherapy for people with advanced small cell lung cancer that has gotten worse after previous treatments. It aims to see if this combination can help control the cancer.
Hear when a new Small Cell Carcinoma of Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.